- Home
- INVA
INVA
Innoviva Inc.
as 10-17-2024 4:00pm EST
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.2B | IPO Year: | 2004 |
| Target Price: | N/A | AVG Volume (30 days): | 618.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.05 | EPS Growth: | -22.53 |
| 52 Week Low/High: | $12.22 - $20.37 | Next Earning Date: | 10-30-2024 |
| Revenue: | $330,496,000 | Revenue Growth: | 13.80% |
| Revenue Growth (this year): | 11.25% | Revenue Growth (next year): | 0.57% |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
Argus Research
9 days ago
INVA: Raising target price to $21.00
Simply Wall St.
18 days ago
Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Business Wire
a month ago
Innoviva to Participate in Upcoming Investor Conferences
Argus Research
2 months ago
INVA: Raising target price to $20.00
Argus Research
2 months ago
INVA: What does Argus have to say about INVA?
Associated Press Finance
3 months ago
Innoviva: Q2 Earnings Snapshot
Business Wire
3 months ago
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
Argus Research
3 months ago
INVA: Raising target price to $19.00
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.